Sanofi SNY announced that the FDA has accepted ... tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis (nrSPMS) and slow disability accumulation independent of relapse ...

Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three ...

According to CEO Daniel Vitt, clinical and disability-related outcomes are more relevant than brain volume change for drug ...

Sanofi announces tolebrutinib phase 3 study data published in NEJM shows benefit on disability progression in multiple sclerosis: Paris Thursday, April 10, 2025, 10:00 Hrs [IST] T ...

for adult patients with relapsing-remitting multiple sclerosis. While Sanofi's list price of Aubagio is set at £13,529 ($22,100) per patient a year, NICE was able to recommend it for the NHS ...

Sanofi (Nasdaq: SNY ... We Are ILL redefines what “sick” looks like by making the multiple sclerosis (MS) community more inclusive and by involving Black women in the conversations surrounding ...

Hoffman-LaRoche, Novartis, and Sanofi. Source Reference: Oh J, et al "Tolebrutinib versus teriflunomide in relapsing multiple sclerosis" N Engl J Med 2025; DOI: 10.1056/NEJMoa2415985.

Sanofi SNY announced that the FDA has accepted its regulatory filing seeking approval for its investigational BTK inhibitor tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis ...